Who are D-138's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mecobalamin IM injection, Methylcobalamin (methylB12), Methyl B12, SAMe, Hydroxocobalamin Chloride Injection, Etoricoxib + Cyanocobalamin fixed dose.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cholesterol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

D-138 — Competitive Intelligence Brief

D-138 (CHOLESTEROL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin B12 [EPC]. Area: Metabolic.

marketed Vitamin B12 [EPC] Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

D-138 (CHOLESTEROL) — DNA Labs, Inc..

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
D-138 TARGET	CHOLESTEROL	DNA Labs, Inc.	marketed	Vitamin B12 [EPC]
Mecobalamin IM injection	Mecobalamin IM injection	Eisai Co., Ltd.	marketed	Vitamin B12 analog	Methionine synthase; B12-dependent enzymes
Methylcobalamin (methylB12)	Methylcobalamin (methylB12)	Arkansas Children's Hospital Research Institute	marketed	Vitamin B12 supplement / Cobalamin	Methionine synthase; methylmalonyl-CoA mutase cofactor
Methyl B12	Methyl B12	University of California, San Francisco	marketed	Vitamin B12 supplement	Methionine synthase
SAMe	SAMe	Mclean Hospital	marketed	Vitamin B12 [EPC]	Methyltransferases
Hydroxocobalamin Chloride Injection	Hydroxocobalamin Chloride Injection	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	phase 3	Vitamin B12 (cobalamin) supplement	Cobalamin-dependent enzymes (methionine synthase, methylmalonyl-CoA mutase)
Etoricoxib + Cyanocobalamin fixed dose	Etoricoxib + Cyanocobalamin fixed dose	Laboratorios Silanes S.A. de C.V.	phase 3	COX-2 selective inhibitor + vitamin B12 supplement	COX-2 enzyme; cyanocobalamin (B12 cofactor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin B12 [EPC] class)

DNA Labs, Inc. · 1 drug in this class
Mclean Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). D-138 — Competitive Intelligence Brief. https://druglandscape.com/ci/cholesterol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab